C/EBPβ enhances platinum resistance of ovarian cancer cells by reprogramming H3K79 methylation

Chemoresistance is a major unmet clinical obstacle in ovarian cancer treatment. Epigenetics plays a pivotal role in regulating the malignant phenotype, and has the potential in developing therapeutically valuable targets that improve the dismal outcome of this disease. Here we show that a series of transcription factors, including C/EBPβ, GCM1, and GATA1, could act as potential modulators of histone methylation in tumor cells. Of note, C/EBPβ, an independent prognostic factor for patients with ovarian cancer, mediates an important mechanism through which epigenetic enzyme modifies groups of functionally related genes in a context-dependent manner. By recruiting the methyltransferase DOT1L, C/EBPβ can maintain an open chromatin state by H3K79 methylation of multiple drug-resistance genes, thereby augmenting the chemoresistance of tumor cells. Therefore, we propose a new path against cancer epigenetics in which identifying and targeting the key regulators of epigenetics such as C/EBPβ may provide more precise therapeutic options in ovarian cancer.In ovarian cancer, the mechanism of chemoresistance is a key question. Here, the authors demonstrate that C/EBPβ and DOT1L together increase methylation of H3K79, which upregulates expression of oncogenic genes and drives poor platinum response and poor survival in ovarian cancer.

[1]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[2]  Paul Theodor Pyl,et al.  HTSeq—a Python framework to work with high-throughput sequencing data , 2014, bioRxiv.

[3]  Robert Brown,et al.  Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling , 2012, Oncogene.

[4]  D. Marsh,et al.  Histones and Their Modifications in Ovarian Cancer – Drivers of Disease and Therapeutic Targets , 2014, Front. Oncol..

[5]  R. Glasspool,et al.  Epigenetics as a mechanism driving polygenic clinical drug resistance , 2006, British Journal of Cancer.

[6]  R. Kuang,et al.  Platinum-Sensitive Recurrence in Ovarian Cancer: The Role of Tumor Microenvironment , 2013, Front. Oncol..

[7]  J. Sage,et al.  C/EBPβ cooperates with RB:E2F to implement RasV12‐induced cellular senescence , 2005 .

[8]  A. Leutz,et al.  Rapamycin and the transcription factor C/EBPβ as a switch in osteoclast differentiation: implications for lytic bone diseases , 2009, Journal of Molecular Medicine.

[9]  Andrea J. O'Hara,et al.  The genomics and genetics of endometrial cancer. , 2012, Advances in genomics and genetics.

[10]  S. Armstrong,et al.  AF10 regulates progressive H3K79 methylation and HOX gene expression in diverse AML subtypes. , 2014, Cancer cell.

[11]  Peter A. Jones,et al.  Epigenetics in cancer. , 2010, Carcinogenesis.

[12]  Brigitte M. Ronnett,et al.  The Histologic Type and Stage Distribution of Ovarian Carcinomas of Surface Epithelial Origin , 2004, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[13]  Yong Fang,et al.  Triggering of death receptor apoptotic signaling by human papillomavirus 16 E2 protein in cervical cancer cell lines is mediated by interaction with c-FLIP , 2010, Apoptosis.

[14]  Jisoo Park,et al.  PKB-mediated PHF20 phosphorylation on Ser291 is required for p53 function in DNA damage. , 2013, Cellular signalling.

[15]  B. Kong,et al.  PAX8 is a novel marker for differentiating between various types of tumor, particularly ovarian epithelial carcinomas , 2013, Oncology letters.

[16]  J. Russo,et al.  SATB1 reprogrammes gene expression to promote breast tumour growth and metastasis , 2008, Nature.

[17]  A. G. de Herreros,et al.  LOXL2 Is Highly Expressed in Cancer-Associated Fibroblasts and Associates to Poor Colon Cancer Survival , 2015, Clinical Cancer Research.

[18]  T. Fojo.  Multiple paths to a drug resistance phenotype: mutations, translocations, deletions and amplification of coding genes or promoter regions, epigenetic changes and microRNAs. , 2007, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[19]  Tian-Li Wang,et al.  Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma , 2010, Science.

[20]  Elizabeth M. Freeburg,et al.  Resistance to cisplatin does not affect sensitivity of human ovarian cancer cell lines to mifepristone cytotoxicity , 2009, Cancer Cell International.

[21]  Joshy George,et al.  Whole–genome characterization of chemoresistant ovarian cancer , 2015, Nature.

[22]  Matthieu Schapira,et al.  Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors , 2012, Nature Communications.

[23]  C. Allis,et al.  Methylation of lysine 4 on histone H3: intricacy of writing and reading a single epigenetic mark. , 2007, Molecular cell.

[24]  David D. L. Bowtell,et al.  The genesis and evolution of high-grade serous ovarian cancer , 2010, Nature Reviews Cancer.

[25]  M. Goldberg,et al.  The nucleoporin 153, a novel factor in double-strand break repair and DNA damage response , 2012, Oncogene.

[26]  M. Post.  Identification of Molecular Pathway Aberrations in Uterine Serous Carcinoma by Genome-wide Analyses , 2013 .

[27]  K. Hess,et al.  Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. , 2011, JAMA.

[28]  T. Reid,et al.  Rewriting the Epigenetic Code for Tumor Resensitization: A Review , 2014, Translational oncology.

[29]  Julien Sage,et al.  C/EBPbeta cooperates with RB:E2F to implement Ras(V12)-induced cellular senescence. , 2005, The EMBO journal.

[30]  Mandi M. Murph,et al.  Molecular Epigenetics in the Management of Ovarian Cancer: Are We Investigating a Rational Clinical Promise? , 2014, Front. Oncol..

[31]  Teresa L. Mastracci,et al.  Genomic alterations in lobular neoplasia: A microarray comparative genomic hybridization signature for early neoplastic proliferationin the breast , 2006, Genes, chromosomes & cancer.

[32]  Likun Du,et al.  A regulatory role for the cohesin loader NIPBL in nonhomologous end joining during immunoglobulin class switch recombination , 2013, The Journal of experimental medicine.

[33]  G. Mills,et al.  XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells. , 2001, Cancer research.

[34]  Yi Zhang,et al.  The diverse functions of Dot1 and H3K79 methylation. , 2011, Genes & development.

[35]  M. Ingelman-Sundberg,et al.  Epigenetic mechanisms of importance for drug treatment. , 2014, Trends in pharmacological sciences.

[36]  C. Sander,et al.  Evaluating cell lines as tumour models by comparison of genomic profiles , 2013, Nature Communications.

[37]  James D. Brenton,et al.  Ovarian Cancer Cell Line Panel (OCCP): Clinical Importance of In Vitro Morphological Subtypes , 2014, PloS one.

[38]  I. Shih,et al.  Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm. , 2011, Human pathology.

[39]  Charles Swanton,et al.  Cancer: evolution within a lifetime. , 2014, Annual review of genetics.

[40]  Marc D. Perry,et al.  ChIP-seq guidelines and practices of the ENCODE and modENCODE consortia , 2012, Genome research.

[41]  John G Doench,et al.  DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia , 2015, Nature Medicine.

[42]  L. Teimoori-Toolabi,et al.  Molecular alterations contributing to pancreatic cancer chemoresistance. , 2017, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

[43]  F. Schmidt,et al.  Screening analysis of ubiquitin ligases reveals G2E3 as a potential target for chemosensitizing cancer cells , 2014, Oncotarget.

[44]  Jing Wang,et al.  Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo , 2010, Cancer biology & therapy.

[45]  B. Garcia,et al.  Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemia. , 2014, Blood.

[46]  C. Zahnow,et al.  CCAAT/enhancer-binding protein β: its role in breast cancer and associations with receptor tyrosine kinases , 2009, Expert Reviews in Molecular Medicine.

[47]  S. Ou,et al.  Will the Requirement by the US FDA to Simultaneously Co-Develop Companion Diagnostics (CDx) Delay the Approval of Receptor Tyrosine Kinase Inhibitors for RTK-Rearranged (ROS1-, RET-, AXL-, PDGFR-α-, NTRK1-) Non-Small Cell Lung Cancer Globally? , 2014, Front. Oncol..

[48]  M. Nachtigal,et al.  Primary culture of ovarian surface epithelial cells and ascites-derived ovarian cancer cells from patients , 2006, Nature Protocols.

[49]  J. Whetstine,et al.  Histone lysine methylation dynamics: establishment, regulation, and biological impact. , 2012, Molecular cell.

[50]  Benjamin Haibe-Kains,et al.  curatedOvarianData: clinically annotated data for the ovarian cancer transcriptome , 2013, Database J. Biol. Databases Curation.

[51]  A. Jemal,et al.  Cancer statistics, 2017 , 2017, CA: a cancer journal for clinicians.

[52]  AmrZ is a global transcriptional regulator implicated in iron uptake and environmental adaption in P. fluorescens F113 , 2014, BMC Genomics.

[53]  K. Brown,et al.  Ataxia-Telangiectasia, Mutated (ATM)/Nuclear Factor κ Light Chain Enhancer of Activated B Cells (NFκB) Signaling Controls Basal and DNA Damage-induced Transglutaminase 2 Expression* , 2012, The Journal of Biological Chemistry.

[54]  J. Kigawa.  New Strategy for Overcoming Resistance to Chemotherapy of Ovarian Cancer , 2013, Yonago acta medica.

[55]  Cyrus Martin,et al.  The diverse functions of histone lysine methylation , 2005, Nature Reviews Molecular Cell Biology.

[56]  S. Shariat,et al.  Genetic determinants for chemo- and radiotherapy resistance in bladder cancer , 2017, Translational andrology and urology.

[57]  O. O’Connor,et al.  Epigenetics and Lymphoma: Can We Use Epigenetics to Prime or Reset Chemoresistant Lymphoma Programs? , 2015, Current Oncology Reports.

[58]  J. Ellenberg,et al.  RNF168 Binds and Amplifies Ubiquitin Conjugates on Damaged Chromosomes to Allow Accumulation of Repair Proteins , 2009, Cell.

[59]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[60]  K. Brand,et al.  Regulation of C/EBPβ and resulting functions in cells of the monocytic lineage. , 2012, Cellular signalling.

[61]  D. Ma,et al.  SIX1 promotes tumor lymphangiogenesis by coordinating TGFβ signals that increase expression of VEGF-C. , 2014, Cancer research.

[62]  Yong Fang,et al.  miR-9 regulation of BRCA1 and ovarian cancer sensitivity to cisplatin and PARP inhibition. , 2013, Journal of the National Cancer Institute.

[63]  S. Howell,et al.  Differential potentiation of alkylating and platinating agent cytotoxicity in human ovarian carcinoma cells by glutathione depletion. , 1985, Cancer research.

[64]  D. Ma,et al.  Sine oculis homeobox homolog 1 promotes α5β1-mediated invasive migration and metastasis of cervical cancer cells. , 2014, Biochemical and biophysical research communications.

[65]  V. Velculescu,et al.  Beyond genomics: critical evaluation of cell line utility for ovarian cancer research. , 2015, Gynecologic oncology.

[66]  M. Bjørås,et al.  Loss of Neil3, the major DNA glycosylase activity for removal of hydantoins in single stranded DNA, reduces cellular proliferation and sensitizes cells to genotoxic stress. , 2013, Biochimica et biophysica acta.

[67]  C. Creighton,et al.  High-grade serous ovarian cancer arises from fallopian tube in a mouse model , 2012, Proceedings of the National Academy of Sciences.

[68]  L. Galluzzi,et al.  Molecular mechanisms of cisplatin resistance , 2012, Oncogene.

[69]  W. Cho,et al.  MicroRNA as Regulators of Cancer Stem Cells and Chemoresistance in Colorectal Cancer. , 2016, Current cancer drug targets.

[70]  Robert Brown,et al.  The Acquisition of hMLH1 Methylation in Plasma DNA after Chemotherapy Predicts Poor Survival for Ovarian Cancer Patients , 2004, Clinical Cancer Research.

[71]  Robert C. Wolpert,et al.  A Review of the , 1985 .

[72]  I. Shih,et al.  The Dualistic Model of Ovarian Carcinogenesis: Revisited, Revised, and Expanded. , 2016, The American journal of pathology.

[73]  C. Cinti,et al.  Targeting Cancer with Epi-Drugs: A Precision Medicine Perspective. , 2016, Current pharmaceutical biotechnology.